Familial hypertrophic cardiomyopathy (FHCM) is an autosomal dominant disease affecting primarily the myocardium. The gene responsible for FHCM has been localized to chromosome 14 in some families and several mutations have been described in the betamyosin heavy chain (beta MHC), a candidate gene for the disease. We recently identified a family with HCM in whom we did not detect any of the known mutations in the beta MHC gene (the alpha/beta MHC hybrid gene and the missense mutation in exons 13 and 9). However, we did observe a novel 9.5-kb BamHI restriction fragment length polymorphism detected by a beta MHC probe on Southern blots of DNA from the proband of this family. Similarly, a novel 3.8-kb TaqI polymorphism and a novel 4.3-kb HindIII polymorphism were detected on Southern blots of DNA from the same proband. Polymerase chain reaction (PCR) was used to amplify the segment of the beta MHC that was detected by pSC14 probe. PCR amplification of the distal 3'-end of the beta MHC gene yielded an additional product in the DNA template from the proband which was subsequently cloned and sequenced. The sequence analysis showed a 2.4-kb nucleotide deletion involving one allele of the beta MHC gene. The deletion includes part of the intron 39, exon 40 including the 3'-untranslated region and the polyadenylation signal, and part of […] 
Introduction
Familial hypertrophic cardiomyopathy (FHCM)' is an autosomal dominant disease that affects primarily the myocardium, resulting in inappropriate growth and hypertrophy. While it is a cause of heart failure later in life, in the young it is a common 1. Abbreviations used in this paper: FHCM, familial hypertrophic BMHC, ,B-myosin heavy chain; RFLP restriction fragment length polymorphism; RT PCR, reverse transcription polymerase chain reaction.
cause of sudden death and is the most common cause in young athletes (1) . The pathological, hemodynamic, and clinical manifestations of HCM have been studied extensively for decades (2) . The myriad of manifestations reflective of diverse pathophysiology include asymmetrical and concentric hypertrophy, decreased myocardial compliance, and outflow tract obstruction. HCM represents a paradigm ofcardiac pathophysiology and elucidation of its molecular basis should provide information fundamental to our understanding of the biology and pathology of the myocardium. The gene responsible for FHCM has been localized in some families to chromosome 14 (3) (4) (5) (6) , and the f3-myosin heavy chain (i3MHC) gene has been identified as the candidate gene for this disease (3) (4) (5) . Three mutations in #MHC gene in two families with FHCM have been described. The first, an a/f3 cardiac myosin hybrid gene described by Tanigawa et al. (7) occurred in all affected members of a single family with FHCM as a result of a crossover event between a-and flMHC genes occurred on exon 27. A missense mutation in exon 13 of fMHC gene has been found in all affected members of another family with FHCM (8) . Similarly, another missense mutation in exon 9 of the ,BMHC gene has been described in a family with FHCM (9) . We have examined DNA from the probands of 59 families with FHCM and have detected the exon 13 missense mutation in a single family, but did not detect the a/l hybrid gene in any family.
However, during this study, we identified a unique restriction fragment length polymorphism (RFLP) on Southern blots of the DNA ofa small family in whom the proband has HCM and showed that it was inherited in a Mendelian manner in two subsequent generations. Using polymerase chain reaction (PCR) to amplify DNA from the proband, we have determined that the RFLP represents a deletion in the f3MHC gene. The deletion is 2.4 kb long and extends from intron 39 of the f3MHC gene into the intergenic region between the #-and aMHC genes. Included within the deletion is exon 40 which contains coding sequence for the carboxy-terminal five amino acids, the stop codon, and entire 3'-untranslated sequence.
Methods
Patient studies. Patient evaluation was done as previously reported (5) . Briefly, the proband and all members of family 151 (pedigree depicted on the top portion of Fig. 2 ) were given detailed cardiovascular examinations and two-dimensional echocardiography. The min. The mixture was quickly cooled on ice, and the cleavage products were ethanol precipitated and lyophilized. Chemical cleavage products were resuspended in formamide and electrophoresed on a 12% denaturing polyacrylamide gel. An autoradiogram was developed from the gel for detection of base mismatches in the heteroduplexes using conventional methodology.
Results
Clinical characteristics. The pedigree of this family has been depicted on the upper portion of Fig. 2 (Fig. 3 ). This implied a deletion, 2.4 kb in size (4.7 kb -2.3 kb), in one ,B-myosin allele of the proband genome. In order to further delineate the location ofthis deletion, the published restriction map ofthe ,BMHC gene sequence (12) and the restriction map ofthe f3/aMHC intergenic resion (C. C.
Liew, personal communication) were reviewed, in the region of the 4.7-kb product which showed absence ofrestriction sites for BamHI, HindIll, or TaqI restriction endonucleases, but the presence of two restriction sites for EcoRI restriction endonuclease. Digestion of the 4.7-kb product with EcoRI restriction endonuclease showed three products of 3.4 kb and 844 and 507 bp while digestion ofthe 2.3-kb product with the EcoRI restriction endonuclease produced three products of 1 kb, 844 bp, and 507 bp (Fig. 4) , the last two identical to the normal map and the 1-kb product being a truncated product of the 3. and nucleotide 26,627 ofthe f3/ aMHC intergenic region. Therefore, a new set ofprimers were designed to flank this region and amplification with PCR (reaction E) produced the expected 3.4-kb product from normal DNA template and proband DNA template, and an additional 1-kb product in the proband DNA. PCR amplification of DNA isolated from all members of the pedigree 151 was performed and the 1-kb product was found to be present in those family members with the novel restriction fragments on Southern blot (Fig. 5) . Cloning and sequencing analysis. To precisely localize the extent of the observed deletion, PCR primers with the asymmetric internal restriction sites at the 5' ends flanking the deletion were used to amplify this region of the DNA from the proband. The PCR product was cloned into pGEM4Z and sequenced. The sequence analysis revealed a 2.4-kb deletion extending from nucleotide 23,793 of the J3MHC gene through nucleotide 26,171 of the intergenic region, between a-and ,3MHC genes, which includes part of intron 39, and all of exon 40 which contains the coding sequence for the 3' carboxy terminal amino acids as well as the entire 3' untranslated region (Fig.  6) . The deletion extends 1,833 nucleotides into the region 5' to the aMHC gene. The deleted region is flanked by a 45-bp direct repeat with 96% positional identity in the normal allele. The downstream repeated sequences are deleted in the mutant allele.
Transcription analysis. In an attempt to determine whether mRNA for the mutant ,BMHC gene allele is transcribed we performed reverse transcription PCR (RT-PCR) on mRNA extracted from a biceps muscle biopsy obtained from the proband of pedigree 151. After extraction of total RNA from the biopsy sample, cDNA for the normal allele was made using reverse transcriptase with the antisense primer to exon 40 and subsequently amplified by PCR using an exon 38 sense primer.
This yielded the expected product of 239 bp (Fig. 7) which was cloned, sequenced, and confirmed to be a transcription product of the normal allele. A potential second polyadenylation signal sequence is located 1.7 kb downstream from the 3'-end of the deletion in the f3/a myosin intragenic region (Fig. 6) . We attempted to make first-strand cDNA from the abnormal allele using antisense primers to the second polyadenylation signal, second 3'-untranslated region, and oligonucleotide dT primer. : ; z ,to Z Figure 5 . 
Discussion
We have detected a 2. We are concerned that in none of the three offsprings is there evidence of HCM despite having inherited the defect. It is possible that the disease in the proband is due to mutations other than the deletion in the 3' end of the f3MHC gene described above. Based on our analysis with RFLP and that of PCR, we have excluded any other mutation that would have involved significant rearrangement in the 3MHC gene. The known mutations of the 3MHC gene, the af/lMHC hybrid gene, and the missense mutations in exons 9 and 13, were excluded (7) (8) (9) . In addition, the results ofchemical cleavage analysis showed no mutations in exons 7, 8, and 9. Screening ofthe whole ,3MHC gene for single nucleotide mutations by a technique such as chemical cleavage (the most sensitive) may require years of study, considering that the j3MHC gene is 24 kb in length. It is not possible to perform linkage analysis to confirm a chromosome 14 disease locus in this family due to its small size. Collection of several families may be difficult because it would appear that this deletion mutation is not a common cause of FHCM. We have examined 59 probands and only one proband had the deletion mutation.
Our unsuccessful attempts to demonstrate transcription from the mutant allele do not exclude production of a mutant mRNA. Our failure to detect a transcript using RT PCR amplification may have resulted from the inability to choose the correct antisense primer for reverse transcription from the mutant mRNA for first-strand cDNA synthesis since all potential splice junctions cannot be cleaved from DNA sequence analysis. It is not evident from DNA sequence analysis where transcription ofthe mutant allele if it is made would terminate. We chose to make an antisense primer complementary to the sequence around and including a polyadenylation signal 1.7 kb downstream from the 3'-end of the deletion. This is the first polyadenylation sequence downstream from the end of the de- letion. In addition, a second antisense universal oligo dT primer was used to prime cDNA synthesis which was also without success. The other possibility is the low abundance and/or instability ofthe mutant mRNA eluded isolation and detection by PCR and electrophoretic analysis.
It is, thus, not possible given the small size ofthe family, the insensitivity of clinical diagnosis, and the inability to detect a transcript from the mutant allele to conclusively prove that the deletion mutation is responsible for the HCM in this family. Whether the deletion is responsible for the disease is further complicated by the observation that the proband did not de- kb deletion is the cause of HCM in this family these results suggest testable hypotheses for the role of the carboxyl terminus of 3-myosin in sarcomere assembly and function. It is intriguing that such a large deletion, involving 10% ofthe gene, is inherited in subsequent generations in which individuals may or may not be affected, and those that are affected, not until much later in life. Does this mean that only the normal allele is being translated? If so, why so? Expression of mutant 3MHC gene constructs in appropriate experimental systems will permit us to examine the role of the 3'-untranslated sequences and polyadenylation on the stability of f-myosin mRNA. Expression ofan in-frame deletion ofthe carboxyl-terminal amino acids will provide insights to the role of these amino acids on the assembly and function of mammalian sarcomeres. We are currently designing studies to examine these questions.
